Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
复制标题
DOI：
10.1158/2326-6066.cir-20-0051
复制
发表时间：
2020-10-01
影响因子：
10.1
通讯作者：
Sakagami, Takuro
中科院分区：
文献类型：
--
作者：
Tomita, Yusuke;Ikeda, Tokunori;Sakagami, Takuro
抗生素引起的肠道生态失调损害了对免疫检查点阻断（ICB）的反应。肠道微生物群正在成为癌症的一个有吸引力的治疗靶点。丁酸梭菌MIYAIRI 588菌株是一种益生菌疗法，用于改善日本与益生菌诱导的生态失调相关的症状。我们假设，益生菌酪酸梭菌治疗（CBT）可能会影响ICBs的治疗效果。我们回顾性评价了118例在熊本大学医院（日本熊本熊本市）接受ICB治疗的晚期非小细胞肺癌患者。采用单变量分析和考克斯比例风险回归模型（使用倾向评分），对ICB之前和/或之后给予CBT的患者进行生存分析。倾向评分分析证实，益生菌CBT显着延长无进展生存期（PFS）和总生存期（OS）。即使在接受抗生素治疗的患者中，益生菌CBT也与PFS和OS延长显著相关。这项研究表明，益生菌CBT可能对ICB在癌症患者中的治疗效果产生积极影响。
Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB). Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium butyricum MIYAIRI 588 strain is a probiotic therapy used to improve symptoms related to antibiotic-induced dysbiosis in Japan. We hypothesized that probiotic Clostridium butyricum therapy (CBT) may affect the therapeutic efficacy of ICBs. We retrospectively evaluated 118 patients with advanced non-small cell lung cancer treated with ICBs at Kumamoto University Hospital (Kumamoto-shi, Kumamoto, Japan). Survival analysis comparing patients given CBT before and/or after ICB was conducted using univariate analyses and Cox proportional hazards regression models using propensity score. Propensity score analyses confirmed that probioticCBTsignificantly prolonged progression-free survival (PFS) and overall survival (OS). Probiotic CBT significantly associated with longer PFS and OS even in patients who received antibiotic therapy. This study suggests that probiotic CBT may have a positive impact on therapeutic efficacy of ICB in patients with cancer.